Novartis AG Q1 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Pharmaceuticals | Market Cap: ₹2.9L Cr
- Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competition in the U.S. - Novartis expects **5% to 6% sales CAGR from 2025 to 2030**, despite patent expiries and U.S.
From Novartis AG's Q1 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹151.4
Market Cap
₹2.9L Cr
P/E Ratio
21.6
Revenue Rank
Margin Rank
How does Novartis AG rank in Pharmaceuticals?
Compare Novartis AG against every Pharmaceuticals company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 4- →Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competition in the U.S. in the first half of 2026.
- →Mid-single-digit sales growth is expected in the second half of 2026, leading to a full-year low single-digit growth overall.
- →The company projects a 5% to 6% compounded annual growth rate (CAGR) in sales from 2025 through 2030, including impacts from generic entries and U.S. MFN agreements.
- →Growth is anticipated to be driven by priority brands, pipeline assets (e.g., lanalumab, Pluvicto, pelacarsen, Avidity assets), and global expansions such as Leqvio in China.
- →Cosentyx is forecasted to grow on average at mid-single-digit rates toward an $8 billion peak sales potential.
- →The cardiovascular portfolio, especially with new oral therapies and pipeline advances, also offers significant growth opportunities.
📈 Profitability & Margins
Rank 3- →Novartis expects **5% to 6% sales CAGR from 2025 to 2030**, despite patent expiries and U.S. MFN impacts.
- →For **2026**, sales are projected to grow **low single digit**, with **core operating income expected to decline low single digits** due to a tough prior-year base and generic competition.
- →Core net financial expenses are forecasted around **$1.7 billion in 2026**, higher than 2025, mainly due to funding costs related to the Avidity deal.
- →Core tax rate is expected to remain around **16.5%**.
- →Novartis aims to **return to 40% plus core margin by 2029**, supported by strong product launches and productivity programs.
- →Core EPS grew **17% to $8.98 in 2025** and is expected to continue growth aligned with sales and margin trends.
- →The company maintains confidence in delivering **mid- to long-term growth** driven by pipeline advances and priority brands.
🏗️ Capital Expenditure Plans
Yes- →Novartis invested over $10 billion in R&D in 2025, an 8% increase compared to the prior year, focusing on strengthening key platforms and pipelines across their four therapeutic areas.
- →The company completed a $15 billion share buyback program in early July 2025 and launched a new up to $10 billion share buyback program targeted for completion by the end of 2027, with approximately $7.7 billion remaining to be executed.
- →Novartis announced 4 acquisitions and 10 licensing deals in 2025, focusing on cardiovascular, immunology, neuroscience, and oncology assets, aiming to build and diversify their pipeline.
- →The anticipated funding costs related to the Avidity Biosciences deal, expected to close in the first half of 2026, will be primarily debt-funded, leading to higher net financial expenses (~$1.7 billion in 2026).
- →Strategic focus continues on advancing key pipeline assets like ianalumab, pelacarsen, and radioligand therapies, signaling ongoing capital and resource allocation toward late-stage development projects.
💰 Fundraising & Capital Structure
No information- →For 2026, Novartis expects core net financial income expenses to be around $1.7 billion, which is higher than 2025 levels.
- →The increase in financial expenses is largely due to anticipated funding costs related to the Avidity deal.
- →The Avidity deal is primarily going to be debt funded.
- →Novartis does not mention any plans for equity fundraising in the provided text.
- →The company continues to invest in R&D and acquisitions, supported by strong free cash flow generation.
- →Novartis remains focused on balanced shareholder-friendly capital allocation, including dividends and share buybacks.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Pharmaceuticals this season
- Haleon plc (Q1 FY26)
Haleon plc Q1 FY26 quarterly results analysis. Organic sales growth guidance for 2026 is 3% to 5%, signaling some sequential acceleration from 3% in 2025. Marke
- Takeda Pharmaceutical Company Limited (Q1 FY26)
Takeda Pharmaceutical Company Limited Q1 FY26 quarterly results analysis. Growth in plasma-derived therapies (PDT) expected to be mid-single-digit growth for th
- Novo Nordisk A/S (Q1 FY26)
Novo Nordisk A/S Q1 FY26 quarterly results analysis. 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at consta
- Sanofi (Q1 FY26)
Sanofi Q1 FY26 quarterly results analysis. For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster tha
Frequently Asked Questions
What were Novartis AG Q1 FY26 results?
- Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competition in the U.S. - Novartis expects **5% to 6% sales CAGR from 2025 to 2030**, despite patent expiries and U.S.
What is Novartis AG share price analysis?
Novartis AG currently shows a neutral. The stock trades at a P/E of 21.6 with a market cap of $288,894. Investors should review the full earnings analysis for detailed insights.
Is Novartis AG planning capital expenditure?
- Novartis invested over $10 billion in R&D in 2025, an 8% increase compared to the prior year, focusing on strengthening key platforms and pipelines across their four therapeutic areas.
Keep Novartis AG on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.